secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000917520-24-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q4 GAAP EPS $0.25 vs $0.63; guides FY2024 revenue up 4-5% organic
--------------------------------------------------------------------------------

- Q4 revenues $397.0M, down 0.2% reported; organic revenue ex-Boston up 3.6%.
- GAAP EPS $0.25, adjusted EPS $0.89 vs $0.94 prior year.
- Full-year 2023 adjusted EPS $3.10 vs $3.36; Boston relaunch on track for mid-to-late Q2 2024.
- Signed definitive agreement to acquire Acclarent ENT business expected to close by Q2 2024.
- FY2024 guidance: revenue $1,603M-$1,618M (organic +4-5%), adjusted EPS $3.15-$3.25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/0000917520-24-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/iart-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000917520-24-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer